Calls for papers
-
Pfizer UK has announced that it has signed an exclusive agreement with Novartis to market the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in the UK for the treatment of COPD. Seebri… Read more . . .
-
Inhaler monitoring company Propeller Health (formerly Asthmapolis) has announced that it raised $14.5 million in a Series B financing round led by Safeguard Scientifics. Safeguard Managing Director Gary J. Kurtzman will join Propeller Health’s board… Read more . . .
-
The FDA has granted fast track designation to Aradigm’s Pulmaquin dual release inhaled ciprofloxacin for treatment of chronic Pseudomonas aeruginosa lung infections in non-cystic fibrosis bronchiectasis patients, the company said. Aradigm initiated a second Phase… Read more . . .
-
Kamada has announced that still plans to hold discussions with the EMA and FDA regarding regulatory submissions for its inhaled Alpha-1 antitrypsin (AAT) even after the drug failed to meet either its primary or secondary… Read more . . .
-
Powder characterization specialists Freeman Technology have announced the opening of an office in Shanghai and the appointment of Joey Xie as Product Manager and Chief Representative in China. The company added that it has also… Read more . . .
-
Teva has announced that the UK High Court has invalidated AstraZeneca’s patent titled “Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma” (EP 1,085,877), which… Read more . . .
-
Cipla has announced the launch of its Serroflo salmeterol/fluticasone MDI, a generic version of Advair, in Germany and Sweden. The inhaler will be available in 25/125 mcg and 25/250 mcg versions, both of which will… Read more . . .
-
Prosonix has submitted an MAA for its PSX1001 fluticasone propionate MDI for the treatment of asthma, triggering a milestone payment from Mylan, the company has announced. In April 2014, Mylan acquired marketing rights for PSX1001… Read more . . .
-
3M Drug Delivery Systems is marking the 25th anniversary of the launch of the Aerolin Autohaler breath-activated salbutamol (albuterol) MDI. According to the company, over 120 million units of the Autohaler device have been manufactured… Read more . . .
-
Contract development company MedPharm has announced a new fast track service for topical formulation development, including for respiratory delivery. The company offers development services for a variety of OINDP formulations, including MDIs, DPIs, inhalation solutions,… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden